# Mechanisms of Weight Loss With SGLT2 Inhibition

> **NCT02360774** · PHASE4 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Type 2 Diabetes
- Overweight
- Obesity

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02360774
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360774, "Mechanisms of Weight Loss With SGLT2 Inhibition". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02360774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*